Can results from a Japanese pulmonary hypertension registry have an impact on Western guidelines?

Respir Investig. 2018 Jul;56(4):263-264. doi: 10.1016/j.resinv.2018.02.004. Epub 2018 Mar 13.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angioplasty, Balloon
  • Cyclic Nucleotide Phosphodiesterases, Type 1 / genetics
  • Drug Therapy, Combination
  • Endarterectomy
  • Epoprostenol / administration & dosage
  • Genome-Wide Association Study
  • Hemodynamics
  • Humans
  • Hypertension, Pulmonary / genetics
  • Hypertension, Pulmonary / physiopathology
  • Hypertension, Pulmonary / therapy*
  • Japan
  • Molecular Targeted Therapy
  • Phenylpropionates / administration & dosage
  • Phosphodiesterase 5 Inhibitors / administration & dosage
  • Practice Guidelines as Topic
  • Pulmonary Embolism / therapy
  • Pyridazines / administration & dosage
  • Randomized Controlled Trials as Topic
  • Registries*
  • Sildenafil Citrate / administration & dosage
  • Tadalafil / administration & dosage

Substances

  • Phenylpropionates
  • Phosphodiesterase 5 Inhibitors
  • Pyridazines
  • Tadalafil
  • Sildenafil Citrate
  • Epoprostenol
  • Cyclic Nucleotide Phosphodiesterases, Type 1
  • PDE1A protein, human
  • ambrisentan